as 12-06-2024 4:00pm EST
Stocks
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
Founded: | 2005 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 3.4M | IPO Year: | 2024 |
Target Price: | N/A | AVG Volume (30 days): | 151.4K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.42 | EPS Growth: | N/A |
52 Week Low/High: | $0.77 - $1.97 | Next Earning Date: | 12-17-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
PLRZ Breaking Stock News: Dive into PLRZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
ACCESSWIRE
a month ago
GlobeNewswire
a month ago
The information presented on this page, "PLRZ POLYRIZON LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.